Cipla launches ashtha inhaler therapy in the US

Pharma giant Cipla Ltd said it received final approval for launching a generic version of
Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.

The product is available for shipping immediately, Cipla said.

Pulmicort Respules and generic equivalents had U.S. sales of approximately $825M for the 12-
month period ending September 2017, making them fairly large in terms of sales.

Budesonide Inhalation Suspension will be launched in three dosages — 0.25mg/2mL, 0.5mg/2mL and 1mg/2mL and are the AN-rated generic equivalents of Astrazeneca’s Pulmicort Respules.

It is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age.

Cipla is present in India as well as across more than 80 countries and sells over 1500 products across wide range of therapeutic categories.